Exploratory study of Coronary Flow Reserve measurements, a non-invasive method for coronary function measurements
Study identifier:D1840M00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, double-blind, placebo-controlled study to evaluate the transthoracic Doppler echocardiography method as a non-invasive method for coronary function measurements; ability to detect short-term statin effects in patients with increased cardiovascular risk
Medical condition
Atherosclerosis
Phase
N/A
Healthy volunteers
No
Study drug
Rosuvastatin, Placebo
Sex
All
Actual Enrollment
80
Study type
Interventional
Age
45 Years - 75 Years
Date
Study Start Date: 01 Oct 2008
Primary Completion Date: -
Study Completion Date: 01 May 2009
Study design
Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 | Drug: Rosuvastatin 40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open). Other Name: Crestor |
| Placebo Comparator: 2 | Drug: Placebo Tablet, oral, once daily for 1 month (double blind) |
Contacts
Investigators
Principal Investigator
Björn Fagerberg
Wallenberg LaboratorySahlgrenska University Hospital, S-413 45 Göteborg
